We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of BridgeBio Pharma in a report issued on Monday, February 24th. Leerink Partnrs analyst M.

BridgeBio Pharma (BBIO) stock in focus as its 2024 spinout BridgeBio Oncology merges with Helix to form go public on Nasdaq ...

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports ...

BofA raised the firm’s price target on BridgeBio (BBIO) to $46 from $45 and keeps a Buy rating on the shares after accounting for the updated ...

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biotechnology company with a market capitalization of $6.85 billion, has been making significant strides in its drug development pipeline and ...

Long term debt management strategy will strengthen the balance sheet without increasing total liabilities - Refinancing term ...

BridgeBio Pharma (BBIO) announces $500M convertible notes offering to repay debt, reduce interest expenses, and boost flexibility.

But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...